Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 29 2022 - 4:01PM
Business Wire
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the
development of medicines that control the expression of genes,
today announced the grant of restricted stock unit (RSU) awards for
an aggregate of 136,750 shares of Syros common stock to six newly
hired employees in connection with their commencement of employment
with Syros. These RSUs were granted as material inducements to
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted on April 29, 2022, vest as to one-quarter
of the shares on April 30, 2023 and as to an additional one quarter
of the shares at the end of each successive year thereafter subject
to the employee’s continued service with Syros, and are subject to
the terms and conditions of a restricted stock unit agreement
covering the award and Syros’ 2022 Inducement Stock Incentive
Plan.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors and blood cancers. Syros also has multiple preclinical
and discovery programs in oncology and monogenic diseases. For more
information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220429005035/en/
Media Courtney Solberg Syros Pharmaceuticals 917-698-9253
csolberg@syros.com
Investor Hannah Deresiewicz Stern Investor Relations,
Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024